The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in Comparison to Standard Therapy in a Veteran Population by Warshawsky, Isaac
Butler University 
Digital Commons @ Butler University 
Undergraduate Honors Thesis Collection Undergraduate Honors Thesis Collection 
2020 
The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in 
Comparison to Standard Therapy in a Veteran Population 
Isaac Warshawsky 
Butler University 
Follow this and additional works at: https://digitalcommons.butler.edu/ugtheses 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Warshawsky, Isaac, "The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in Comparison to 
Standard Therapy in a Veteran Population" (2020). Undergraduate Honors Thesis Collection. 527. 
https://digitalcommons.butler.edu/ugtheses/527 
This Thesis is brought to you for free and open access by the Undergraduate Honors Thesis Collection at Digital 
Commons @ Butler University. It has been accepted for inclusion in Undergraduate Honors Thesis Collection by an 
authorized administrator of Digital Commons @ Butler University. For more information, please contact 
digitalscholarship@butler.edu. 
BUTLER UNIVERSITY HONORS PROGRAM 
 
Honors Thesis Certification 
 
 
Please type all information in this section: 
 
Applicant Isaac Wai Lun Warshawsky        
  (Name as it is to appear on diploma) 
 
Thesis title The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in  
 
 Comparison to Standard Therapy in a Veteran Population 
 
  
 
Intended date of commencement May 9, 2020 
 
 
 
Read, approved, and signed by: 
 
Thesis adviser(s)   
     Date 
   
     Date 
Reader(s)    
     Date 
    
     Date 
 
Certified by 
  Director, Honors Program   Date 
 
 
 
 
 
 
 
The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in Comparison to 
Standard Therapy in a Veteran Population 
 
 
 
 
 
 
 
A Thesis Presented to 
 
The College of Pharmacy and Health Sciences 
 
And 
 
The Honors Program 
 
of 
 
Butler University 
 
 
 
 
 
 
 
In Partial Fulfillment 
 
of the Requirements for Graduation Honors 
 
 
 
 
 
 
Isaac Wai Lun Warshawsky 
 
May 9, 2020 
 
 
 
Warshawsky 2 
 
 
Acknowledgements 
 The completion of this thesis would not have been possible without the help and 
support of Dr. Darin Ramsey, who served as the faculty advisor and guided the direction 
of the research as a whole. I would also like to extend a thank you to Dr. Shelby Beutel 
Darrow for collecting and analyzing the data for the comparator group in this study and 
for assisting in this completion of this research project. Special thanks to Dr. Chad 
Knoderer for serving as the second thesis reader and assisting with the statistical analysis, 
Dr. Chad Naville-Cook for his help with the data collection, and Dr. Jason Lantzer for his 
mentorship throughout my time in the Butler Honors Program. 
Warshawsky 3 
 
 
Table of Contents 
Abstract…………………………………………………………………………………... 4 
Introduction 
Diabetes Mellitus Overview……………………………………………………………….5 
Treatment Guidelines……………………………………………………………………... 6 
GLP-1 Receptor Agonists………………………………………………………………… 7 
VA Medical Center Formulary…………………………………………………………… 9 
Objectives………………………………………………………………………………….9 
Methods 
Data Collection………………………………………………………………………….. 10 
Primary and Secondary Outcomes………………………………………………………. 11 
Inclusion and Exclusion Criteria………………………………………………………… 11 
Statistical Analysis………………………………………………………………………. 12 
Results 
Table 1: Baseline Demographics …………………………………………………….......14 
Table 2: Results.………………………………………………………………………….15 
Discussion………………………………………………………………………………..17 
Conclusion……………………………………………………………………………….20 
References………………………………………………………………………………. 21 
Warshawsky 4 
 
 
Abstract 
Background: Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) present a novel 
therapy for use in Type 2 Diabetes Mellitus (T2DM) patients to reduce Hemoglobin A1c 
(HbA1c) and weight. GLP-1 RAs are more expensive compared to other therapeutic 
options for diabetes and are not currently on the national formulary for Veterans Affairs 
medical centers. This study looks to explore the efficacy data in a veteran population. 
Objectives: The specific aim of this study is to determine the change in HbA1c and 
weight in T2DM patients taking GLP-1 RAs compared to Standard Therapy with insulin 
and Oral Antidiabetic Drugs (OADs) at 26 weeks. Secondary objectives include 
comparing change in HbA1c, weight, and BMI at 52 weeks to validate the efficacy of 
GLP-1 RAs in the veteran population. 
Methods: This research study is a retrospective cohort electronic medical record (EMR) 
review conducted at the Richard L. Roudebush Veterans Affairs Medical Center in 
Indianapolis, Indiana. The study compared data points from two cohorts of patients:  
1. GLP-1 RA: patients treated with liraglutide or exenatide 
2. Standard Therapy: patients treated with insulin detemir and/or insulin glargine 
Results: In the first 26 weeks for the Standard Therapy group, HbA1c changed on 
average by -0.9%, weight by +2.41 kg, and BMI by +0.78 kg/m2. In comparison, at 26 
weeks for the GLP-1 RA group, HbA1c changed on average -1.34%, weight by -2.40 kg, 
and BMI by -0.7 kg/m2. At 52 weeks for the Standard Therapy group, HbA1c changed on 
average by -0.74%, weight by +1.26 kg, and BMI by +0.46 kg/m2 from baseline. At 52 
weeks for the GLP-1 RA group, HbA1c changed on average by -1.31%, weight by -4.06 
kg, and BMI by -1.36 kg/m2 from baseline. 
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Introduction 
Diabetes Mellitus Overview 
Diabetes Mellitus results from an inability to metabolize sugars and starch, which 
results in abnormally high blood glucose levels known as hyperglycemia. Common forms 
of Diabetes Mellitus include Prediabetes, Gestational Diabetes, Type 1, and Type 2—this 
research is specifically focused on the Type 2 Diabetes Mellitus (T2DM) patient 
population. T2DM is the most common form of diabetes, affecting approximately 90% of 
diabetic patients.1 The pathophysiology of T2DM involves the development of insulin 
resistance, which differs from Type 1 Diabetes Mellitus (T1DM) patients where the body 
becomes unable to produce insulin due to an autoimmune disorder.2 Patients who are at 
increased risk for developing T2DM include those who are overweight or obese, 45 years 
of age or older, have high blood pressure, low level High-Density Lipoprotein (HDL) 
cholesterol, high level triglycerides, history of heart attack or stroke, or family history of 
diabetes.3  
Patients who do not adequately treat or manage their T2DM are at risk for both 
macrovascular and microvascular complications, damage to the large blood vessels and 
small blood vessels respectively. Macrovascular complications include coronary artery 
disease, peripheral arterial disease, and stroke; whereas microvascular complications 
include diabetic nephropathy (kidneys), neuropathy (nerves), and retinopathy (eyes). 
Diabetic complications are not only debilitating for the patients, they also present a 
significant economic burden: $22.9 billion per year.4 As a result, patients are typically 
instructed to closely monitor their blood glucose daily to improve glycemic control and 
therefore limit potential complications. The goal pre-prandial range for blood glucose in 
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diabetic patients is 80-130 mg/dL, and patients who stay within the target range reduce 
the risk for microvascular and macrovascular complications.5 While patients often self-
monitor their blood glucose, lab tests measuring Hemoglobin A1c (HbA1c) allow health 
practitioners to identify the average blood glucose for the patient within a 3-month time 
frame. The American Diabetes Association (ADA) guidelines recommend that patients 
aim for a target HbA1c < 7 percent, which correlates to an average blood glucose of 
approximately < 154 mg/dL. Measuring HbA1c has become a standard in assessing the 
diabetes management of patients because it provides data points that self-blood glucose 
monitoring may lack due to nonadherence to testing regimens. A decrease in HbA1c is 
representative of less microvascular and macrovascular damage due to tighter glucose 
control.6 
 
Treatment Guidelines 
 Before patients are prescribed pharmacologic therapies to treat T2DM, 
nonpharmacologic treatment is encouraged. Obesity management has been shown to 
increase glycemic control, leading to lower HbA1c and improved health outcomes. 
Patients are encouraged to achieve a caloric deficit of 500-750kcal/day, utilize behavioral 
therapy, and exercise (200-300 minutes of physical activity per week) with the goal of 
achieving and maintaining a >5% weight loss.6,8 The Indianapolis VA Medical Center 
implements a VA MOVE! Program that patients may sign up for to monitor their exercise 
goals and receive physical activity regimens. 
 For T2DM patients who struggle to maintain glycemic control, nonpharmacologic 
therapies often times are insufficient. Therefore, for those patients, pharmacologic 
treatments are utilized alongside diet, exercise, and behavioral therapy. Metformin has 
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been established as the 1st line pharmacologic treatment for T2DM patients; however, 
metformin is titrated up to a therapeutic dose due to dose-dependent gastrointestinal 
disturbances that may lead to discontinuation if intolerable. For patients unable to achieve 
diabetic control with metformin within 3 months, discontinue metformin, or are 
contraindicated to taking metformin, GLP-1 RAs are recommended as the 1st line therapy 
according to the American Diabetes Association (ADA) Guidelines. If heart failure or 
chronic kidney disease predominate health concerns, Sodium-Glucose Transport Protein 
2 (SGLT2) inhibitors are preferred. GLP-1 RAs are also recommended for use in 
combination with metformin and an SGLT-2 inhibitor for patients with persistent 
hyperglycemia.7 
 
GLP-1 Receptor Agonists 
In response to oral dietary intake, the body produces incretin hormones to 
enhance insulin secretion to lower blood glucose levels. Incretins also reduce insulin 
release when glucose levels are within normal range, thereby reducing the risk of 
hypoglycemia, the common, life-threatening adverse effect of many diabetic medications. 
Glucagon-like peptide 1 is an incretin hormone that has been seen to decrease glucagon 
concentrations, improve insulin sensitivity, slow gastric emptying, increase satiety, and 
decrease body weight. GLP-1 receptor agonists act by stimulating the receptors and 
potentiating the incretin effects.8 
The following GLP-1 RAs are currently FDA approved: exenatide (Byetta®, 
Bydureon®), liraglutide (Victoza®, Saxenda®), lixisenatide (Lyxumia®), albiglutide 
(Tanzeum®), dulaglutide (Trulicity®), and semaglutide (Ozempic®, Rybelsus®). With the 
exception of Rybelsus®, a once-daily tablet that was FDA approved in September 2019, 
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all GLP-1 RAs are administered subcutaneously with a dosing frequency ranging from 
twice daily to once weekly. Common side effects of GLP-1 RAs are nausea, vomiting, 
and diarrhea. GLP-1 RAs are also used concomitantly with other diabetic medications, 
which often include insulin and OADs. The two GLP-1 RAs included in this study were 
liraglutide and exenatide. Liraglutide is dosed as 0.6mg, 1.2mg, and 1.8mg once weekly 
injections; whereas, exenatide is dosed as 5μg or 10μg twice daily and 2μg extended 
release once weekly. Additionally, twice daily exenatide requires dosing within 1 hour 
before meals, while extended release exenatide and liraglutide may be administered 
without regard to mealtime.9-1610111213141516  
According to published literature, a 6-week study which compared an infusion of 
normal saline versus GLP-1 in patients with T2DM on no other diabetic medication 
resulted in an average reduction in HbA1c of 1.3% and an average weight loss of 1.9 
kg.17 In this study, a GLP-1 RA was not used, rather a subcutaneous injection of GLP-1 
incretin hormone was administered via a continuous subcutaneous infusion. A review of 
head-to-head GLP-1 RA studies uncovered that the therapy results in an average HbA1c 
reduction of 0.78% to 1.9% at 26 weeks.18 A meta-analysis of GLP-1 RAs in 2015 
displayed an average reduction in weight of 1.01kg to 1.62kg over 26 weeks.19 When 
comparing liraglutide and exenatide in combination with metformin or a sulfonylurea, a 
26-week study showed a reduction in HbA1c of 1.12% for liraglutide and 0.79% for 
exenatide. The average reduction in weight was very similar between the two GLP-1 RAs 
groups: 3.24kg for liraglutide and 2.87kg for exenatide.20 Another 26-week trial 
investigated the use of liraglutide 1.8mg alongside insulin and/or OADs compared to 
placebo and/or OADs. The trial displayed a decrease in HbA1c of 0.9% with liraglutide 
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compared to a decrease of 0.4% for the non-GLP-1 RA group, which represents a 
reduction in HbA1c of 0.5% with the addition of liraglutide.15  
 
Veterans Affairs Formulary 
Due to their high cost in comparison to other therapies on the market, GLP-1 RAs 
were traditionally reserved once insulin, along with other oral therapies, had failed to 
reduce HbA1c. However, recent guidelines from the ADA now recommend treatment 
with GLP-1 RAs after standard metformin therapy for most patients. Despite the 
recommendation for GLP-1 RA use, at the time of this study, they were excluded on the 
VA national formulary and therefore are less accessible for patient use.21 Formulary-
excluded medications have higher costs for patients due to lower reimbursement rates and 
are less likely to be stocked in the pharmacy and available for patients. The prevalence of 
T2DM has been noted to be higher in the veteran population than the general US 
population: 25% compared to 20.5% respectively. Possibly due to multiple factors, the 
high rate of obesity amongst the veteran population is suspected to be a key contributor to 
the increased incidence of diabetes.22 Data demonstrating the value of GLP-1 RAs in 
improving diabetes health outcomes in the veteran population may encourage the 
decision to include these therapies on the national formulary. 
 
Objectives 
The specific aim of this study is to determine the change in HbA1c and weight in 
T2DM patients taking GLP-1 RAs compared to Standard Therapy with insulin and OADs 
at 26 weeks. Secondary objectives include comparing change in HbA1c, weight, and 
BMI at 52 weeks to validate the efficacy of GLP-1 RAs in the veteran population. 
Warshawsky 10 
 
 
Methods 
Data Collection 
This research study was a retrospective cohort electronic medical record (EMR) 
review conducted at the Richard L. Roudebush Veterans Affairs Medical Center in 
Indianapolis, Indiana. The Decentralized Hospital Computer Program (DHCP) was used 
to generate a list of patients within the inclusion parameters of the study and data was 
obtained from the Computerized Patient Record System (CPRS). The study compared 
data points from two cohorts of patients:  
1. GLP-1 RA: patients treated with liraglutide or exenatide23  
2. Standard Therapy: patients treated with insulin detemir and/or insulin 
glargine, excluding those treated with a GLP-1 RA 
The data points were arranged in categories of 0, 1, 2, 3, 6, 9, 12, 16, 20, 24, 30, 
36, 42, and 48 months. Data collected at 6 months and 12 months were assumed to be 
equivalent to 26 weeks and 52 weeks respectively. For each group, the following data 
points were collected for each of the above months that the data was available: specific 
drug used in diabetes management (insulin or GLP-1 receptor agonist) and dose, patient 
weight, BMI, HbA1c, other oral diabetes medications, enrollment in the VA MOVE! 
Program, and total daily units used of both long-acting and short-acting insulin 
requirements.  
Due to the retrospective nature of this study, no direct patient enrollment was 
needed for study participation. For the GLP-1 RA group, a confidential list of 90 patients 
was generated by the DHCP record system in the outpatient pharmacy. For the Standard 
Therapy group, the list generated by DHCP included approximately 7000 patients based 
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on the inclusion criteria. From the list, patients were randomly selected by every 100 
patients, resulting in approximately 70 subjects for data analysis.  
 
Outcomes 
Primary Outcomes  
The change in HbA1c and weight at 26 weeks in patients on insulin and/or OADs 
compared to patients with the addition of GLP-1 RAs. 
Secondary Outcomes  
The change in HbA1c, weight, and BMI at 52 weeks in patients on insulin and/or OADs 
compared to patients with the addition of GLP-1 RAs. 
 
Inclusion and Exclusion Criteria 
Inclusion criteria  
GLP-1 RA group: Patients at the Indianapolis VAMC with a diagnosis of T2DM 
and use of a GLP-1-RA, ages 18-80 from the date range: 1/1/2010 – 9/1/17. Those on two 
separate GLP-1 agonists for two distinct time periods were included.  
Standard Therapy group: Patients at the Indianapolis VAMC with a diagnosis of 
T2DM and use of insulin detemir and/or insulin glargine, ages 18-80 from the date range: 
1/1/2010 – 9/1/2017 were compared. 
Exclusion criteria  
Patients with type 1 diabetes mellitus, patients who discontinued a GLP-1 RA within the 
first month, lack of baseline and/or follow up data points for HbA1c and/or weight. 
 Standard Therapy Group: Patients using a GLP-1 RA were excluded. 
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Statistical Analysis 
Statistical analysis was conducted using Statistical Package for Social Sciences 
(SPSS) version 26 software. Nominal data (MOVE! Program enrollment and specific use 
of other diabetes medications) were evaluated with Chi square to identify potential 
confounding factors or abnormal distribution. Descriptive statistics were used to describe 
group characteristics. Continuous interval data (HbA1c comparison, weight, BMI) were 
evaluated using independent sample t-test, with p-values <0.05 considered statistically 
significant, and Mann-Whitney U for non-normally distributed data. 
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Results 
 The GLP-1 RA group included 80 patients during the study period, 19 of which 
were excluded due to insufficient A1c and weight data. 10 of the 19 excluded patients 
discontinued use of a GLP-1 RA within one month of initiation. The GLP-1 RA group 
included 4 patients (6.6%) on exenatide and 57 patients (93.4%) on liraglutide. Of the 4 
patients on exenatide, one used the once-weekly formulation (Bydureon®), whereas the 
other 3 patients used the twice-daily formulation (Byetta®).23 When collecting data for 
the Standard Therapy group, due to the 7000 patients eligible within the inclusion 
parameters, patients were randomized and then excluded as needed until 61 patients were 
obtained to meet the number set by the GLP-1 RA group. 
 The baseline demographics (Table 1) of the Standard Therapy group and the 
GLP-1 RA group were comparable in terms of distribution of sex, enrollment in the VA 
MOVE! Program, and age. The average baseline HbA1c was also similar between the 
two groups: 9.25% for the Standard Therapy group and 9.07% for the GLP-1 RA group. 
In contrast, the weight and BMI were higher in the GLP-1 RA group: 126.6 kg and 40.5 
kg/m2 compared to 104.5 kg and 33.3 kg/m2 in the Standard Therapy group. Additionally, 
more patients in the GLP-1 RA group were taking Metformin within their regimen 
(93.4% versus 54.1% in the Standard Therapy group). Patients in the GLP-1 RA group 
were also taking, on average, 1 – 2 more OADs at baseline than patients in the Standard 
Therapy group. 
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_ 
In the first 26 weeks for the Standard Therapy group, HbA1c changed on average 
by -0.9% [95% Confidence Interval: -1.54, -0.27], weight by +2.41 kg [-1.04, 5.86], and 
BMI by +0.78 kg/m2 [-0.38, 1.94]. In comparison, at 26 weeks for the GLP-1 RA group, 
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HbA1c changed on average -1.34% [-1.78, -0.91], weight by -2.40 kg [-3.88, -0.92], and 
BMI by -0.7 kg/m2 [-1.19, -0.21]. At 52 weeks for the Standard Therapy group, HbA1c 
changed on average by -0.74% [-1.40, -0.08], weight by +1.26 kg [-2.13, 4.65], and BMI 
by +0.46 kg/m2 [-0.66, 1.58] from baseline. At 52 weeks for the GLP-1 RA group, 
HbA1c changed on average by -1.31% [-1.81, -0.81], weight by -4.06 kg [-6.55, -1.58], 
and BMI by -1.36 kg/m2 [-2.19, -0.54] from baseline.  
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Statistical analysis showed that the change in HbA1c for both 26 weeks and 52 
weeks were not statistically significant (p = 0.157 and p = 0.154 respectively). However, 
both change in weight and BMI from baseline at weeks 26 and 52 were statistically 
significant, with p values < 0.05.  
Discontinuation of GLP-1-RAs were most often due to GI intolerance (7%), 
combined prescriber and patient decisions (4%), and miscellaneous factors (4%). All five 
of the patients who discontinued GLP-1-RAs due to GI intolerance stopped within the 
first month of use. The majority (72%) of patients continued GLP-1-RA use through the 
study. Miscellaneous factors for discontinuation included pancreatitis, concern for cancer, 
dislike of needles, provider change, bariatric surgery, relocation, and death. There were 
no patients in this study who discontinued GLP-1-RAs due to cost.23  
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Discussion 
Findings from the GLP-1 RA cohort suggest a decrease in HbA1c of 1.34% at 26 
weeks, which is comparable to published literature showing a reduction in HbA1c of 
0.78% to 1.9% at 26 weeks.18 There was a -0.44% difference in HbA1c between the GLP-
1 RA group versus standard therapy at 26 weeks in this study, which is fairly similar to 
the HbA1c reduction in a clinical trial studying the addition of liraglutide to standard 
therapy: -0.5%.15 However, the difference in HbA1c in this study between the GLP-1 RA 
group and the Standard Therapy group lacked statistical significance, which inhibits its 
generalizability. A meta-analysis of GLP-1 RAs in 2015 showed an average change in 
weight of -1.01kg to -1.62kg over 26 weeks.20 In comparison, this study produced greater 
weight loss results as the GLP-1 RA group had a change in weight of -2.40 kg at 26 
weeks. Overall, the findings of this study shows a similar HbA1c reduction and a larger 
weight reduction in the veteran population compared to published data. 
Although VA Medical Centers currently exclude GLP-1 RAs from formulary, the 
results of this study present statistically significant reduction in weight and BMI over a 
26 week and 52 week period in the veteran population. If the reduction in HbA1c were 
statistically significant, the data would further establish a reason to increase accessibility 
of GLP-1 RAs for veterans. With the current ADA guidelines promoting GLP-1 RAs as 
preferred therapies after metformin, an increasing number of diabetic patients have begun 
using GLP-1 RAs. With an increase in patient use comes an increase in real-world 
evidence, which may clarify the benefits of using a GLP-1 RA on HbA1c, weight, and 
BMI.  
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However, lack of formulary access may, in turn, hinder the amount of real-world 
evidence available due to the limited use of GLP-1 RAs.  
From a formulary management perspective, a reduction in weight is beneficial for 
a T2DM patient, but HbA1c reduction is deemed more important. Despite the 
cardiovascular benefits that come along with weight loss, HbA1c reduction results in less 
macrovascular and microvascular complications. These complications can result in 
hospitalizations which can, in turn, lead to morbidity and mortality for the patient and are 
also costly to the payer. 
 
Strengths 
 This study is very applicable to veterans because the patients included were 
patients treated within the VA Medical Center in Indianapolis. Due to the random 
selection of enrollment, specifically for the standard therapy group, the data is 
representative of the veteran population. The statistical significance of both the difference 
in weight and BMI at 26 and 52 weeks serves as a strength of this study.   
 
Limitations 
 Although the Standard Therapy and GLP-1 RA groups were comparable for 
certain demographics, they varied in baseline data for average total daily dose of insulin, 
weight, BMI, Metformin use, and number of OADs. Additionally, only two GLP-1 RAs 
were tested in this study, which may limit the generalizability to the therapeutic class 
outside of liraglutide and exenatide. Additionally, there were few patients on exenatide 
compared to liraglutide, which lessens the applicability of the study results to patients 
using exenatide. Although SGLT-2 inhibitors are used often in current practice due to 
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their 1st line place in therapy after Metformin use, there were no patients in either group 
who were using an SGLT-2 inhibitor at baseline. SGLT-2 inhibitors are commonly used 
in combination with GLP-1 RAs to achieve greater glycemic control, and it would be 
interesting to further explore a cohort on SGLT-2 inhibitor therapy. Cardiovascular 
benefit is becoming increasingly important for diabetic treatments, so cardiovascular 
outcomes would have been a valuable secondary endpoint to have studied. 
A potential confounding variable involved a change in diabetic regimen leading to 
a further decrease in HbA1c, weight, and/or BMI. For the Standard Therapy group, the 
average OADs increased from 0.84 at baseline to 0.92 at 26 weeks and decreased to 0.75 
at 52 weeks. In comparison, for the GLP-1 RA group, the average OADs decreased from 
1.58 at baseline to 1.25 at 26 weeks and further decreased to 1.23 at 52 weeks. Although 
there was a larger average of OADs in the GLP-1 RA group, the key takeaway revolves 
around the difference in OADs throughout the study period. A decrease in the amount of 
OADs within a patient’s regimen would reduce the overall HbA1c reduction potential 
and could also influence weight/BMI depending on the OAD. 
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Conclusion 
GLP-1 RAs are effective in reducing weight and BMI in the veteran population 
when added in combination to standard therapy. Veterans experience a similar reduction 
in HbA1c when using GLP-1 RAs compared to published data although the difference as 
compared to standard therapy was not statistically significant. Our findings highlight the 
need to further evaluate the benefit of GLP-1 RAs in reducing HbA1c in the veteran 
population. 
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